M8 Pharmaceuticals

What M8 Pharmaceuticals does

M8 Pharmaceuticals, Inc. is a privately held pharmaceutical company headquartered in Berwyn, United States, that develops and commercializes branded medicines for the Latin American market. The company operates under the brand "Acino Latam" (legal name Acino Latinoamericana S.A., domiciled in Brazil) and is a subsidiary of Arcera, a strategic operating parent. Its portfolio includes branded pharmaceutical products such as NABOTA®, a botulinum toxin for therapeutic use, and historically Ultraproct LDO (fluocortolone pivalate, lidocaine hydrochloride), a dermatological product whose registration has been cancelled. The company was founded in 2007 and employs between 251 and 500 people.

The business model centers on partnering with and marketing pharmaceutical products across Latin America, as reflected in its dedicated "We Partner" and "We Market" service lines and its localized Portuguese (Brazil) and Spanish-language digital presence. The company issues regular market announcements covering product lifecycle events including packaging updates, labeling changes, regulatory actions, and supply chain integrity notices (e.g., medication theft notifications in March and May 2025). It maintains an active regulatory and pharmacovigilance posture, with adverse event reporting and transparency disclosures (including a pay equity report) consistent with multinational pharma operating standards.

M8 Pharmaceuticals' go-to-market is fundamentally a B2B pharmaceutical distribution and commercialization platform for the Latam region, leveraging country-level regulatory registrations, localized marketing capabilities, and partnership-driven in-licensing. The company is part of the broader Arcera platform, indicating integration into a larger pharmaceutical operating company's portfolio strategy. No AI/ML, software, or technology-stack capabilities are disclosed in the source material; the business is a traditional branded pharma commercializer.

Name

M8 Pharmaceuticals

Legal name

Acino Latinoamericana S.A.

Website

https://m8pharmaceuticals.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

M8 Pharmaceuticals (operating as Acino Latam) develops and commercializes branded pharmaceutical products — including botulinum toxin (NABOTA®) and dermatological medicines — for the Latin American market as a subsidiary of Arcera.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

Keywords

• Pharmaceutical products
• Branded medicines
• Botulinum toxin
• Dermatological medications
• Pharmaceutical marketing

Headquarters

HQ city

Berwyn

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

M8 Pharmaceuticals (operating as Acino Latam) develops, markets, and commercializes branded pharmaceutical products across Latin America, with a portfolio that includes botulinum toxin (NABOTA®) and dermatological medications such as Ultraproct LDO. The company also offers partnership and marketing services ('We Partner', 'We Market') to pharmaceutical companies seeking to enter or expand within the Latin American market.

Product overview

M8 Pharmaceuticals operates as a pharmaceutical company focused on innovative and proven medicines in Latin America. The company provides product offerings including branded medications such as NABOTA® (botulinum toxin) and Ultraproct LDO, alongside partnership and marketing services for pharmaceutical products in the Latin American market. The portfolio includes market-announced products with regulatory updates and labeling changes.

Differentiator

Problem solved

Functional benefit

Brands

• NABOTA: Product mentioned in market announcements regarding packaging updates

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights3 records

Direct peers

• Eurofarma Laboratórios: Largest privately held Brazilian pharmaceutical company, focused on branded prescription and innovative medicines across Latin America. Direct comparable on geographic footprint (LatAm), therapeutic breadth (multi-specialty branded) and commercialization-only positioning versus pure innovators.
• Hypera Pharma: Leading Brazilian branded pharma company with broad portfolio across consumer health, prescription and specialty therapeutics, exporting across Latin America. Direct regional peer on branded LatAm commercialization model.
• Aché Laboratórios Farmacêuticos: Major Brazilian innovator pharma with branded prescription portfolio sold throughout Brazil and LatAm. Comparable on therapeutic breadth, branded commercial model, and regional reach.
• EMS Pharma: Brazil's largest pharmaceutical company by units, with leading branded and specialty prescription portfolio distributed across Brazil and Latin America. Comparable regional scale, branded distribution model, and multi-therapeutic breadth.

Regional players

• Asofarma (Alfa Sigma Group): Latin American branded pharma player headquartered in Mexico, distributing prescription brands across Central and South America. Comparable on LatAm branded model, though anchored in Mexico/CA rather than Brazil-driven M8 footprint.
• Aspen Pharmacare: South African-headquartered specialty/branded pharma with established Latin American commercial operations. Comparable on emerging-market branded pharma focus and in-licensing commercial model.

Broad incumbents

• Sanofi LatAm: Global pharma major with established LatAm commercial footprint across multiple therapeutic areas. Competes with M8 for branded prescription share and for LatAm in-licensing partners in the same geography.
• Bayer (Consumer Health / Pharma LatAm): Major incumbent with branded pharma and consumer health operations throughout Latin America. Direct competitor in dermatology/consumer health adjacencies relevant to M8's portfolio.

Emerging players

• Galderma: Global dermatology and aesthetics pure-play with growing LatAm presence, including aesthetics/Toxins portfolio (Alluzience, Sculptra). Directly relevant for M8's NABOTA dermatology/aesthetics positioning.
• Evolus: Aesthetic medicine company whose Jeuveau competes head-to-head with botulinum toxin franchises like NABOTA. Most direct specialty competitor for M8's aesthetics positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/AcinoSwiss
• YouTubeyoutube.com/@acinoswiss
• Facebookfacebook.com/acino.swiss
• LinkedInlinkedin.com/company/moksha8
• Instagraminstagram.com/acino.swiss

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about M8 Pharmaceuticals